| Kartic Rajput, MD, PHD | |
|
2545 W Hammer Ln, Stockton, CA 95209-2839 | |
| (209) 941-0371 | |
| (209) 951-2469 |
| Full Name | Kartic Rajput |
|---|---|
| Gender | Male |
| Speciality | Pain Management |
| Experience | 22 Years |
| Location | 2545 W Hammer Ln, Stockton, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1306006705 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208VP0000X | Pain Medicine - Pain Medicine | C160187 (California) | Primary |
| 208VP0014X | Pain Medicine - Interventional Pain Medicine | 27244 (Nebraska) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Sutter Tracy Community Hospital | Tracy, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Sutter Valley Medical Foundation | 9830094515 | 1840 |
News Archive
A Medical College of Wisconsin study provides the strongest and most complete evidence to date of major changes occurring during human development in the types and levels of enzymes responsible for the disposition of drugs and environmental chemicals.
The creatinine clearance (Ccr) test has been used as a gold standard for evaluation of preoperative renal function in patients with gastric cancer. However, it is known that Ccr is not strictly equivalent to glomerular filtration rate (GFR). It has been accepted that estimated GFR (eGFR) is equal to measured GFR in chronic kidney disease. However, there have been no studies regarding the reliability of eGFR as a preoperative renal function test in gastric cancer patients.
Boehringer Ingelheim Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for its angiotensin II receptor blocker (ARB) Micardis® (telmisartan) Tablets 80 mg for reduction of the risk of myocardial infarction, stroke, or death from cardiovascular causes in patients 55 years of age or older at high risk of developing major cardiovascular events who are unable to take angiotensin-converting enzyme (ACE) inhibitors.(1) MICARDIS is the most studied ARB in this high-risk patient population and has been commercially available to treat hypertension (high blood pressure) since its approval in 1998.
"I think it will not surprise you if I say that the immune system is one of our most important organ systems. Its relevance is obvious if only for the fact that it has been reinvented several times throughout the evolution of life," says Professor Andreas Radbruch, President of the German Society of Immunology and Director of the Deutsches Rheuma-Forschungszentrum, Berlin. He lectured about the miracle of our immune system at the Opening Press Conference of the 2nd European Congress of Immunology.
› Verified 4 days ago
| Entity Name | Sutter Valley Medical Foundation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669846986 PECOS PAC ID: 9830094515 Enrollment ID: O20090311000335 |
News Archive
A Medical College of Wisconsin study provides the strongest and most complete evidence to date of major changes occurring during human development in the types and levels of enzymes responsible for the disposition of drugs and environmental chemicals.
The creatinine clearance (Ccr) test has been used as a gold standard for evaluation of preoperative renal function in patients with gastric cancer. However, it is known that Ccr is not strictly equivalent to glomerular filtration rate (GFR). It has been accepted that estimated GFR (eGFR) is equal to measured GFR in chronic kidney disease. However, there have been no studies regarding the reliability of eGFR as a preoperative renal function test in gastric cancer patients.
Boehringer Ingelheim Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for its angiotensin II receptor blocker (ARB) Micardis® (telmisartan) Tablets 80 mg for reduction of the risk of myocardial infarction, stroke, or death from cardiovascular causes in patients 55 years of age or older at high risk of developing major cardiovascular events who are unable to take angiotensin-converting enzyme (ACE) inhibitors.(1) MICARDIS is the most studied ARB in this high-risk patient population and has been commercially available to treat hypertension (high blood pressure) since its approval in 1998.
"I think it will not surprise you if I say that the immune system is one of our most important organ systems. Its relevance is obvious if only for the fact that it has been reinvented several times throughout the evolution of life," says Professor Andreas Radbruch, President of the German Society of Immunology and Director of the Deutsches Rheuma-Forschungszentrum, Berlin. He lectured about the miracle of our immune system at the Opening Press Conference of the 2nd European Congress of Immunology.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kartic Rajput, MD, PHD Po Box 255228, Sacramento, CA 95865-5228 Ph: (800) 470-0071 | Kartic Rajput, MD, PHD 2545 W Hammer Ln, Stockton, CA 95209-2839 Ph: (209) 941-0371 |
News Archive
A Medical College of Wisconsin study provides the strongest and most complete evidence to date of major changes occurring during human development in the types and levels of enzymes responsible for the disposition of drugs and environmental chemicals.
The creatinine clearance (Ccr) test has been used as a gold standard for evaluation of preoperative renal function in patients with gastric cancer. However, it is known that Ccr is not strictly equivalent to glomerular filtration rate (GFR). It has been accepted that estimated GFR (eGFR) is equal to measured GFR in chronic kidney disease. However, there have been no studies regarding the reliability of eGFR as a preoperative renal function test in gastric cancer patients.
Boehringer Ingelheim Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for its angiotensin II receptor blocker (ARB) Micardis® (telmisartan) Tablets 80 mg for reduction of the risk of myocardial infarction, stroke, or death from cardiovascular causes in patients 55 years of age or older at high risk of developing major cardiovascular events who are unable to take angiotensin-converting enzyme (ACE) inhibitors.(1) MICARDIS is the most studied ARB in this high-risk patient population and has been commercially available to treat hypertension (high blood pressure) since its approval in 1998.
"I think it will not surprise you if I say that the immune system is one of our most important organ systems. Its relevance is obvious if only for the fact that it has been reinvented several times throughout the evolution of life," says Professor Andreas Radbruch, President of the German Society of Immunology and Director of the Deutsches Rheuma-Forschungszentrum, Berlin. He lectured about the miracle of our immune system at the Opening Press Conference of the 2nd European Congress of Immunology.
› Verified 4 days ago
Dr. Edward Michael Outlaw, MD Pain Medicine Medicare: Not Enrolled in Medicare Practice Location: 4505 Precissi Ln Ste A, Stockton, CA 95207 Phone: 209-425-3815 | |
Dr. Ravi R Pankhaniya, M.D. Pain Medicine Medicare: Accepting Medicare Assignments Practice Location: 10200 Trinity Pkwy, Suite 206, Stockton, CA 95219 Phone: 209-207-0555 Fax: 209-916-4900 |